IGF1 and Hypsarrhythmia: In animal models, IGF-1 administration effectively eliminates both spasms and hypsarrhythmia, indicating its potential utility as both a therapeutic agent and disease severity biomarker (Ballester-Rosado et al., 2022; Yamada et al., 2014).